Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

4.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.3K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.3K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.

Frontiers in immunology·2026
Same author

Generation of therapeutic T cells from human induced pluripotent stem cells.

Inflammation and regeneration·2026
Same author

IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Stress-induced CXCL13 regulates pancreatic exocrine homeostasis, age-related chronic inflammation, and cancer progression.

Science advances·2026
Same author

Ventricular fibrillation triggered by recurrent hypoglycemia in a patient with insulinoma associated with MEN1: case report and review of literature.

Endocrine journal·2026
Same author

Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation.

Frontiers in immunology·2026

Related Experiment Video

Updated: Aug 22, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

[Development of CAR-T cell therapy using allogeneic iPS cells].

Shin Kaneko1,2

  • 1Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 9, 2022
PubMed
Summary

Allogeneic induced pluripotent stem (iPS) cells offer a promising solution for manufacturing challenges in CAR-T therapy. Generating CAR-T cells from iPS cells could improve stability, quality control, and availability for B-cell malignancies.

Keywords:
Cytotoxic T-cell differentiationHypoimmunogenic CAR T-cellsInduced pluripotent stem cellsXenogeneic component-free manufacturing

More Related Videos

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.6K

Related Experiment Videos

Last Updated: Aug 22, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

8.8K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

18.6K

Area of Science:

  • Immunology
  • Stem Cell Biology
  • Cancer Therapy

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy demonstrates significant efficacy in treating B-cell malignancies.
  • Current CAR-T cell manufacturing faces challenges in stability, quality control, and patient-specific T-cell availability.
  • Allogeneic T-cells present a potential alternative to overcome current manufacturing limitations.

Approach:

  • Utilizing induced pluripotent stem (iPS) cells, which possess self-renewal and pluripotency, as a source for CAR-T cell generation.
  • Developing methods for generating CD8 killer T-cells from allogeneic iPS cells.
  • Investigating gene editing techniques to mitigate allogeneic antigenicity in iPS-derived T-cells for clinical applications.

Key Points:

  • The review explores the induction of CD8 killer T-cells from iPS cells.
  • It discusses strategies to enhance the safety and reliability of this induction process for clinical use.
  • The potential of gene editing to reduce immune rejection of allogeneic iPS T-cells is examined.

Conclusions:

  • Allogeneic iPS cells are a viable source for generating CAR-T cells, addressing manufacturing hurdles.
  • Optimizing the induction and gene editing of iPS-derived T-cells is crucial for clinical translation.
  • This approach holds promise for improving CAR-T therapy accessibility and efficacy in B-cell malignancies.